These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37563240)

  • 41. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
    Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A
    JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
    BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D.
    Lee JY; Kim JW; Lim MC; Kim S; Kim HS; Choi CH; Yi JY; Park SY; Kim BG;
    J Gynecol Oncol; 2019 Nov; 30(6):e112. PubMed ID: 31576697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.
    Sastre J; Massuti B; Pulido G; Guillén-Ponce C; Benavides M; Manzano JL; Reboredo M; Rivera F; Grávalos C; Safont MJ; Martínez Villacampa M; Llovet P; Dotor E; Díaz-Rubio E; Aranda E;
    Eur J Cancer; 2015 Jul; 51(11):1371-80. PubMed ID: 25963019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
    Oh DY; Lee KH; Lee DW; Yoon J; Kim TY; Bang JH; Nam AR; Oh KS; Kim JM; Lee Y; Guthrie V; McCoon P; Li W; Wu S; Zhang Q; Rebelatto MC; Kim JW
    Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):522-532. PubMed ID: 35278356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
    Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
    JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Johnson B; Haymaker CL; Parra ER; Soto LMS; Wang X; Thomas JV; Dasari A; Morris VK; Raghav K; Vilar E; Kee BK; Eng C; Parseghian CM; Wolff RA; Lee Y; Lorenzini D; Laberiano-Fernandez C; Verma A; Lang W; Wistuba II; Futreal A; Kopetz S; Overman MJ
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36007963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Rivera F; Valladares M; Gea S; López-Martínez N
    J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases.
    Wang C; Park J; Ouyang C; Longmate JA; Tajon M; Chao J; Lim D; Sandhu J; Yin HH; Pillai R; Gozo MC; Avalos C; Egelston CA; Lee PP; Fakih M
    Oncologist; 2020 May; 25(5):382-e776. PubMed ID: 31857446
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.
    Gallois C; Emile JF; Kim S; Monterymard C; Gilabert M; Bez J; Lièvre A; Dahan L; Laurent-Puig P; Mineur L; Coriat R; Legoux JL; Hautefeuille V; Phelip JM; Lecomte T; Sokol H; Capron C; Randrian V; Lepage C; Lomenie N; Kurtz C; Taieb J; Tougeron D
    Dig Liver Dis; 2021 Oct; 53(10):1254-1259. PubMed ID: 34215534
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.
    Calabrò L; Rossi G; Morra A; Rosati C; Cutaia O; Daffinà MG; Altomonte M; Di Giacomo AM; Casula M; Fazio C; Palmieri G; Giannarelli D; Covre A; Maio M
    Lancet Respir Med; 2021 Sep; 9(9):969-976. PubMed ID: 33844995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
    Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27).
    Samalin E; Fouchardière C; Thézenas S; Boige V; Senellart H; Guimbaud R; Taïeb J; François E; Galais MP; Lièvre A; Seitz JF; Metges JP; Bouché O; Boissière-Michot F; Lopez-Crapez E; Bibeau F; Ho-Pun-Cheung A; Ychou M; Adenis A; Di Fiore F; Mazard T
    Clin Colorectal Cancer; 2020 Dec; 19(4):301-310.e1. PubMed ID: 32737004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
    Folprecht G; Pericay C; Saunders MP; Thomas A; Lopez Lopez R; Roh JK; Chistyakov V; Höhler T; Kim JS; Hofheinz RD; Ackland SP; Swinson D; Kopp M; Udovitsa D; Hall M; Iveson T; Vogel A; Zalcberg JR
    Ann Oncol; 2016 Jul; 27(7):1273-9. PubMed ID: 27091810
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
    Fuchs CS; Fakih M; Schwartzberg L; Cohn AL; Yee L; Dreisbach L; Kozloff MF; Hei YJ; Galimi F; Pan Y; Haddad V; Hsu CP; Sabin A; Saltz L
    Cancer; 2013 Dec; 119(24):4290-8. PubMed ID: 24122767
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.
    Martini G; Ciardiello D; Dallio M; Famiglietti V; Esposito L; Corte CMD; Napolitano S; Fasano M; Gravina AG; Romano M; Loguercio C; Federico A; Maiello E; Tuccillo C; Morgillo F; Troiani T; Di Maio M; Martinelli E; Ciardiello F
    Int J Cancer; 2022 Aug; 151(3):473-480. PubMed ID: 35429341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for
    He J; Liu Y; Liu C; Hu H; Sun L; Xu D; Li J; Wang J; Chen X; Lin R; Jiang Y; Zhang Y; Zhang W; Cheng Y; Wu X; Fang M; Li E; Xu Y; Chen Y; Li J; Cui Y; Pan Z; Zhang S; Yuan Y; Ding K
    Technol Cancer Res Treat; 2023; 22():15330338231152350. PubMed ID: 36727222
    [No Abstract]   [Full Text] [Related]  

  • 60. mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale.
    Nagata N; Mishima H; Kurosawa S; Oba K; Sakamoto J
    Clin Colorectal Cancer; 2017 Jun; 16(2):154-157.e1. PubMed ID: 28284575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.